Skip to main content
. Author manuscript; available in PMC: 2026 Sep 13.
Published in final edited form as: Eur J Med Chem. 2025 Oct 4;301:118228. doi: 10.1016/j.ejmech.2025.118228

Figure 2: Compounds P374, P404, and P405 significantly reduce TG2 protein levels in ovarian cancer cells.

Figure 2:

(A, B) Western blot analysis of TG2 protein levels in SKOV3 cells treated with compounds P374, P404, and 405 at 0, 0.1, 1, and 10 μM for 24 hours (A) and 72 hours (B). (C, D) Western blot analysis of TG2 in OVCAR5 cells treated with compounds P374, P404, and P405 at 0, 0.1, 1, and 10 μM for 24 hours (C) and 72 hours (D). (E, F) Quantification of TG2 protein levels over time (0, 6, 24, and 72 hours) in SKOV3 (E) and OVCAR5 (F) cells treated with 10 μM of compounds P374, P404, and 405. n = 3 replicates. TG2 level normalized against GAPDH, considereing control as 100%. (G, H) Cell viability of SKOV3 (G) and OVCAR5 (H) cells treated with increasing concentrations (0, 0.1, 0.3, 1, 3, 10, and 30 μM) of compounds P374, P404, and 405. n = 3 replicates. All values represent means ± SD. ****p < 0.0001 by 2 way ANOVA with Tukey post-test.